TO MONITOR TREATMENT OF A LARGE COHORT OF PATIENTS WITH β-THALASSAEMIA MAJOR, INTERMEDIA & SICKLE CELL ANAEMIA IN ORDER TO ESTABLISH THE RESPONSE TO TRANS-RESVERATROL AND THE ASSOCIATED ELEMENTS.
- Department of Genetics, Institute of Genetic Medicine and Genomic Science. 30A Thakurhat Road. Kolkata- 700128, West Bengal, India.
- Department of Genetics, Institute of Genetic Engineering. 30 Thakurhat Road. Kolkata- 700128, West Bengal, India.
- Abstract
- Keywords
- References
- Cite This Article as
- Corresponding Author
Though several genetic, non-genetic and pharmacological factors reported to influence the Trans-Resveratrol response in different early studies, the response to Trans-Resveratrol is significantly different among good, moderate and non-responders irrespective of the IVS I-5 (GC), the common beta mutation here and even among other β0 or β+thalassaemia mutations. Here we study whether HbF level has any relation to beta variants responding to Trans-Resveratrol therapy, it has been shown that even among good responders in some cases (8.39 %) patients are not showing high HbF values ( < 20% HbF values are taken). In our study (among 220 patients), Trans-Resveratrol therapy completely replace blood transfusion in as expected in this Eastern part of India, the predominant β-thalassemia defect is the IVSI-5(GC), the most frequent β0-thal mutation in the area. This mutation is found in 87.66% of the CR patients and in 86.66% of the PR / NR patients. The next represented defects are the β+-thalassemia mutations like Cod 8/9, Fr. 41/42, Cod 15, Cod 30 etc. The common IVSI-5 (GC) mutation in beta thalassemia patients (either in homozygous or heterozygous form) is present in 31.5% among the good responders (CR) while it is present in 66.66% among PR / NR (the moderate responders / non-responders) and in HbE-beta patients present in 73.28% among good responders (CR) while in 33.33% among moderate / non responders (PR / NR).
- De Franceschi L, Bertoldi M, De Falco L, Santos Franco S, Ronzoni L, Turrini F, et al. Oxidative stress modulates heme synthesis and induces peroxiredoxin-2 as a novel cytoprotective response in beta-thalassemic erythropoiesis. Haematologica. 2011;96(11): 1595?604 [PMC free article] [PubMed]
- Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135?46 [PubMed]
- de Franceschi L, Turrini F, Honczarenko M, Ayi K, Rivera A, Fleming MD, et al. In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. Haematologica. 2004;89(11):1287?98 [PubMed]
- De Franceschi L, Ronzoni L, Cappellini MD, Cimmino F, Siciliano A, Alper SL, et al. K-CL co-transport plays an important role in normal and beta thalassemic erythropoiesis. Haematologica. 2007;92(10):1319?26 [PubMed]
- Olivieri O, De Franceschi L, Capellini MD, Girelli D, Corrocher R, Brugnara C. Oxidative damage and erythrocyte membrane transport abnormalities in thalassemias. Blood. 1994; 84(1):315?20 [PubMed]
- Ginzburg Y, Rivella S. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood. 2011;118(16):4321?30 [PMC free article] [PubMed]
- Liu J, Zhang J, Ginzburg Y, Li H, Xue F, De Franceschi L, et al. Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis. Blood. 2013;121(8): e43?9 [PMC free article] [PubMed]
- Fibach E, Rachmilewitz E. The role of oxidative stress in hemolytic anemia. Curr Mol Med. 2008;8(7):609?19 [PubMed]
- Bauer JH, Helfand SL. New tricks of an old molecule: lifespan regulation by p53. Aging cell. 2006;5(5):437?40 [PMC free article] [PubMed]
- Ferry-Dumazet H, Garnier O, Mamani-Matsuda M, Vercauteren J, Belloc F, Billiard C, et al. Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. Carcinogenesis. 2002;23(8):1327?33 [PubMed]
- Rodrigue CM, Arous N, Bachir D, Smith-Ravin J, Romeo PH, Galacteros F, et al. Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation. Br J Haematol. 2001;113(2):500?7 [PubMed]
- Ragione FD, Cucciolla V, Criniti V, Indaco S, Borriello A, Zappia V. p21Cip1 gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J Biol Chem. 2003;278 (26):23360?8 [PubMed]
- Jeong JY, Silver M, Parnes A, Nikiforow S, Berliner N, Vanasse GJ. Resveratrol ameliorates TNFalpha-mediated suppression of erythropoiesis in human CD34(+) cells via modulation of NF-kappaB signalling. Br J Haematol. 2011;155(1):93?101 [PMC free article] [PubMed]
- Ragione FD, Cucciolla V, Borriello A, Pietra VD, Racioppi L, Soldati G, et al. Resveratrol arrests the cell division cycle at S/G2 phase transition. Bioch Biophys Res Com. 1998;250 (1):53?8 [PubMed]
- Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science. 2013;339(6124):1216?9 [PMC free article] [PubMed]
- Marinkovic D, Zhang X, Yalcin S, Luciano JP, Brugnara C, Huber T, et al. Foxo3 is required for the regulation of oxidative stress in erythropoiesis. J Clin Invest. 2007;117(8):2133?44 [PMC free article] [PubMed]
- Nicoletta Bianchi, Cristina Zuccato, Ilaria Lampronti, Monica Borgatti and Roberto Gambari. Fetal Hemoglobin Inducers from the Natural World: A Novel Approach for Identification of Drugs for the Treatment of β-Thalassemia and Sickle-Cell Anemia. Advance Access Publication 11 December 2007 & eCAM 2009;6(2)141?151.
[Anirban Roy Chowdhury, Sudipa Chakravarty and Amit Chakravarty. (2017); TO MONITOR TREATMENT OF A LARGE COHORT OF PATIENTS WITH β-THALASSAEMIA MAJOR, INTERMEDIA & SICKLE CELL ANAEMIA IN ORDER TO ESTABLISH THE RESPONSE TO TRANS-RESVERATROL AND THE ASSOCIATED ELEMENTS. Int. J. of Adv. Res. 5 (Jul). 1190-1194] (ISSN 2320-5407). www.journalijar.com
Institute of Genetic Medicine and Genomic Science.
